Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Kalaris Therapeutics (KLRS) Cash from Investing Activities (2019 - 2020)

Kalaris Therapeutics (KLRS) has 2 years of Cash from Investing Activities data on record, last reported at $1.9 million in Q4 2020.

  • For Q4 2020, Cash from Investing Activities fell 94.49% year-over-year to $1.9 million; the TTM value through Dec 2020 reached -$169.5 million, changed N/A, while the annual FY2024 figure was $95.0 million, 150.1% up from the prior year.
  • Cash from Investing Activities reached $1.9 million in Q4 2020 per KLRS's latest filing, up from -$210.3 million in the prior quarter.
  • Across five years, Cash from Investing Activities topped out at $34.9 million in Q4 2019 and bottomed at -$210.3 million in Q3 2020.